BiocurePharm Looks Beyond North America Via Canada IPO
With a business model that sets it apart from other South Korean bioventures, BiocurePharm plans to set up manufacturing facilities in North America and worldwide with local partners, and is launching a Canadian IPO in a bid to transform into a truly multinational operation, its CEO says.
You may also be interested in...
Stockholm-based Xbrane Biopharma plans to be the first to sell a biosimilar version of Lucentis in Iran as part of its strategy to leverage patent gaps in emerging markets for high-priced drugs.
Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.
South Korea's breakthrough therapy system, Global Innovative Products Fast Track, kicks off with Roche’s follicular lymphoma drug becoming the first to test the new system. Meanwhile, a state-run group is linking with pharma firms to rapidly bring in global new drugs.